Cannascopic Ep 5 - Dr. Brian Murphy, MD, MPH, MBA. Is cannabis effective for treating eye diseases?
In this insightful episode we have an in depth conversation with Dr Brian Murphy the CEO of Emerald Bioscience regarding the pharmaceutical applications of cannabinoids particularly in the treatment of eye diseases.
Dr. Murphy in uniquely qualified to talk on this topic as he has two decades of experience in drug development and evaluation, both from the academic and industry perspective. Prior to his executive leadership at Emerald Bioscience, he most recently served as the CMO of Eiger Biosciences. Previously, Dr. Murphy was CMO at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs, Clinical Development, Biostatistics, and Pharmacovigilance.
Dr Murphy is board-certified in internal medicine and completed his residency at Tufts-New England Medical Center. He served as Chief Medical Resident in the Boston University Internal Medicine program. He went on to complete parallel fellowship tracts at Harvard Medical School (HMS) and the Massachusetts General Hospital in medicine and clinical epidemiology. He also completed a fellowship in Medical Ethics at HMS-Brigham and Women’s Hospital.
Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business. Dr. Murphy is also a member of the Forbes Business Council and a contributor to Forbes Online.
Please take a listen to this fascinating conversation. You will find that in depth conversation on drug development and therapy has never been quite so interesting.
Stock Symbol: EMBI: Emerald Bioscience